Patents by Inventor Gregory L. Verdine

Gregory L. Verdine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250069699
    Abstract: The present disclosure relates to computer-based methods and systems for identifying genes associated with biosynthetic gene clusters (BGCs), including embedded target genes (ETaGs) that are homologs of potential therapeutic targets, using comparative genomics techniques and machine learning models.
    Type: Application
    Filed: May 3, 2024
    Publication date: February 27, 2025
    Inventors: Michalis HADJITHOMAS, Stephen Andrew WYKA, Jinwoo KIM, Yu-Cheng LIN, Iain James MCFADYEN, Gregory L. VERDINE
  • Publication number: 20250069701
    Abstract: The present disclosure relates to computer-implemented methods and systems for identifying biosynthetic gene clusters (BGCs) that encode pathways for the production of secondary metabolites. Secondary metabolites that target genes or gene products that are homologous to, e.g., human genes or gene products may have utility as potential drug compounds.
    Type: Application
    Filed: May 20, 2024
    Publication date: February 27, 2025
    Inventors: Michalis HADJITHOMAS, Michael Qi DING, Demetrius Michael DIMUCCI, Nancy Ann ZHANG, Iain James MCFADYEN, Gregory L. VERDINE
  • Publication number: 20250037800
    Abstract: The present disclosure relates to methods and systems for identifying genes associated with biosynthetic gene clusters (BGCs), including embedded target genes (ETaGs) that are homologs of potential therapeutic targets. The methods and systems described herein apply a comparative genomics and manual review or machine-learning model to analyze grid representations such as heat maps, which assess across a plurality of diverse genomes distribution of orthologs (e.g., bidirectional best hits) of a plurality of query genes that are co-localized with an anchor gene (e.g., a core synthase gene) of a BGC in a query genome.
    Type: Application
    Filed: May 3, 2024
    Publication date: January 30, 2025
    Inventors: Michalis HADJITHOMAS, Stephen Andrew WYKA, Jinwoo KIM, Yu-Cheng LIN, Iain James MCFADYEN, Gregory L. VERDINE
  • Patent number: 12180472
    Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: December 31, 2024
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Meena Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Publication number: 20240376151
    Abstract: The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences. In some embodiments, the present disclosure provides stapled peptide agents and uses thereof including for treating various conditions, disorders or diseases.
    Type: Application
    Filed: October 30, 2023
    Publication date: November 14, 2024
    Inventors: Olena Tokareva, Justin Robert Lawrie, Kunhua Li, Tara Lynne Travaline, Jean-Marie Swiecicki, Gregory L. Verdine, John Hanney McGee, Ty Matthew Thomson
  • Publication number: 20240360179
    Abstract: Among other things, the present disclosure provides various useful agents. In some embodiments, provided agents can bind to beta-catenin. In some embodiments, the present disclosure provides technologies for modulating beta-catenin functions. In some embodiments, the present disclosure provides technologies for preventing and/or treating conditions, disorders or diseases associated with beta-catenin. In some embodiments, the present disclosure provides designed amino acids and agents which can provide improved properties and/or activities.
    Type: Application
    Filed: June 8, 2022
    Publication date: October 31, 2024
    Inventors: Brian Halbert White, Daniel Seungduk La, Lorenzo Josue Alfaro-Lopez, Paula Cristina Ortet, Sarah Isabelle Cappucci, Zhi Li, John Hanney McGee, Martin Robert Tremblay, Gregory L. Verdine, Yaguang Si, Kevin Ling, Peicheng Du, Jonathan Barry Hurov
  • Publication number: 20240299344
    Abstract: The present disclosure relates to treatment of a subject comprising administering to the subject a compound of formula (I); or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 4, 2022
    Publication date: September 12, 2024
    Inventors: Gregory L. Verdine, Jared N. Cumming, Susanne M. Saalau, M. Paola Castaldi, Yoon Choi
  • Publication number: 20240229026
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Application
    Filed: May 5, 2023
    Publication date: July 11, 2024
    Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena ., Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Publication number: 20240212788
    Abstract: Among other things, the present disclosure provides technologies for efficient and effective identification of ETaGs, for example, from fungi genomes. In some embodiments, provided technologies are particularly useful for identifying mammalian targets of biosynthetic products of fungi. In some embodiments, provided technologies are particularly useful for identifying and/or prioritizing human targets for drug development. In some embodiments, provided technologies are particularly useful for developing modulators for human targets based on biosynthetic products of fungi.
    Type: Application
    Filed: July 13, 2023
    Publication date: June 27, 2024
    Inventors: John Baxter BIGGINS, Brian Roger BOWMAN, Gregory L. VERDINE
  • Publication number: 20240124525
    Abstract: The present invention provides a new type of alpha-helix nucleating cross-link (“staple”) formed by olefin metathesis of a proline derivative with an alkenyl side chain and another amino acid derivative with an alkenyl side chain. The proline derivatives as described herein have been found to be strong nucleators of alpha-helix formation. The invention also provides moieties for shielding the free amide N—H's at the N-terminus of an alpha-helix, thereby further stabilizing the helix. The proline derivatives, precursors prior to cross-linking, and the cross-linked peptides are provided as well as methods of using and preparing these compounds and peptides.
    Type: Application
    Filed: August 21, 2023
    Publication date: April 18, 2024
    Inventors: Gregory L. VERDINE, Kazuhiro HAYASHI
  • Publication number: 20240117347
    Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 11, 2024
    Inventors: David Charles Donnell Butler, Sethumadhavan Divakaramenon, Christopher J. Francis, Maria David Frank-Kamenetsky, Naoki Iwamoto, Genliang Lu, Subramanian Marappan, Meena, Chandra Vargeese, Gregory L. Verdine, Hailin Yang, Jason Jingxin Zhang
  • Publication number: 20240044876
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Application
    Filed: March 30, 2023
    Publication date: February 8, 2024
    Inventors: Gregory L. VERDINE, David W. WHITE, David M. ARMISTEAD, Deborah J. PALESTRANT, Brian Y. CHOW, Chris K. VARMA, Mathew Edward SOWA
  • Patent number: 11834482
    Abstract: Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: December 5, 2023
    Assignee: FOG PHARMACEUTICALS, INC.
    Inventors: Gerard Hilinski, So Youn Shim, Matthew Reiser Patton, John Hanney McGee, Paula Cristina Ortet, Gregory L Verdine
  • Publication number: 20230357320
    Abstract: In some embodiments, the present disclosure provides stapled peptides and compositions thereof. In some embodiments, provided peptides can bind to and modulate functions of estrogen receptor.
    Type: Application
    Filed: March 17, 2021
    Publication date: November 9, 2023
    Inventors: Gregory L. Verdine, John Hanney McGee, Santosh Kumar Choudary, Yue-Mei Zhang, Martin Robert Tremblay
  • Patent number: 11749375
    Abstract: Among other things, the present disclosure provides technologies for efficient and effective identification of ETaGs, for example, from fungi genomes. In some embodiments, provided technologies are particularly useful for identifying mammalian targets of biosynthetic products of fungi. In some embodiments, provided technologies are particularly useful for identifying and/or prioritizing human targets for drug development. In some embodiments, provided technologies are particularly useful for developing modulators for human targets based on biosynthetic products of fungi.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: September 5, 2023
    Assignee: LIFEMINE THERAPEUTICS, INC.
    Inventors: John Baxter Biggins, Brian Roger Bowman, Gregory L. Verdine
  • Patent number: 11644460
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: May 9, 2023
    Assignee: Revolution Medicines, Inc.
    Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
  • Patent number: 11643657
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: May 9, 2023
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Publication number: 20230137773
    Abstract: The present invention provides peptides comprising a sequence of X-6X-5X-4X-3X-2X-1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26YLX29X30X31X32 wherein the amino acids X-6, X-5, X-4, X-3, X-2, X-1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.
    Type: Application
    Filed: May 23, 2022
    Publication date: May 4, 2023
    Inventors: Gregory L. VERDINE, John Hanney MCGEE
  • Publication number: 20220372075
    Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.
    Type: Application
    Filed: November 17, 2020
    Publication date: November 24, 2022
    Inventors: Gregory L. VERDINE, Gerard HILINSKI
  • Patent number: 11479797
    Abstract: The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: October 25, 2022
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Daniel C. Gray, Brian R. Bowman, Gregory L. Verdine, Mathew Edward Sowa